Mitochondrial mutations in patients with congenital heart defects by next generation sequencing technology.


Abaci N. , Arikan M., Tansel T. , Sahin N., Cakiris A. , Pacal F. , ...More

Cardiology in the young, vol.25, pp.705-11, 2015 (Journal Indexed in SCI Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 25
  • Publication Date: 2015
  • Doi Number: 10.1017/s1047951114000754
  • Journal Name: Cardiology in the young
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.705-11
  • Keywords: Congenital heart defects, next-generation sequencing, mitochondrial mutations, HEREDITARY OPTIC NEUROPATHY, MTDNA, CARDIOMYOPATHY, MECHANISMS, TRNA(THR), VARIANTS, DISEASE

Abstract

It has been shown that mitochondrial deoxyribo nucleic acid mutations may play an important role in the development of cardiomyopathy, and various types of cardiomyopathy can be attributed to disturbed mitochondrial oxidative energy metabolism. Several studies have described many mutations in mitochondrial genes encoding for subunits of respiratory chain complexes. Thus, recent studies confirm that pathologic mitochondrial deoxyribo nucleic acid mutations are a major reason of diseases and determining them by next-generation sequencing will improve our understanding of dysregulation of heart development. To analyse mitochondrial deoxyribo nucleic acid mutations, the entire mitochondrial deoxyribo nucleic acid was amplified in two overlapping polymerase chain reaction fragments from the cardiac tissue of the 22 patients with congenital heart disease, undergoing cardiac surgery. Mitochondrial deoxyribo nucleic acid was deep sequenced by next-generation sequencing. A total of 13 novel mitochondrial deoxyribo nucleic acid mutations were identified in nine patients. Of the patients, three have novel mutations together with reported cardiomyopathy mutations. In all, 65 mutations were found, and 13 of them were unreported. This study represents the most comprehensive mitochondrial deoxyribo nucleic acid mutational analysis in patients with congenital heart disease.